First-line treatment of chronic hepatitis B with entecavir or tenofovir in `real-life' settings: from clinical trials to clinical practice

Journal of Viral Hepatitis, 05/18/2012

Two real–life studies of TDF reported response rates of 71–92% after up to 21 months of treatment. Low incidences of drug resistance and favourable tolerabilities were reported for both drugs, thus confirming the results from registration trials.

Print Article Summary Cat 2 CME Report